Affordable Access

Access to the full text

Hallux rigidus treated with adipose-derived mesenchymal stem cells: A case report

Authors
  • Braile, Adriano
  • Toro, Giuseppe
  • De Cicco, Annalisa
  • Cecere, Antonio Benedetto
  • Zanchini, Fabio
  • Schiavone Panni, Alfredo
Type
Published Article
Journal
World Journal of Orthopedics
Publisher
Baishideng Publishing Group Co (World Journal of Orthopedics)
Publication Date
Jan 18, 2021
Volume
12
Issue
1
Pages
51–55
Identifiers
DOI: 10.5312/wjo.v12.i1.51
PMID: 33520681
PMCID: PMC7814311
Source
PubMed Central
Keywords
Disciplines
  • Case Report
License
Green

Abstract

BACKGROUND First metatarsophalangeal joint arthritis (FMTPA), also known as hallux rigidus, is the most frequent degenerative disease of the foot. Diagnosis is made through both clinical and radiological evaluation. Regenerative medicine showed promising results in the treatment of early osteoarthritis. The aim of the present study was to report the results of a case of FMTPA treated with the injection of autologous adipose-derived mesenchymal stem cells. CASE SUMMARY A gentleman of 50 years of age presented with a painful hallux rigidus grade 2 resistant to any previous conservative treatment (including nonsteroidal anti-inflammatory drugs and hyaluronic acid injections). An injection of autologous adipose-derived mesenchymal stem cells into the first metatarsophalangeal joint was performed. No adverse events were reported, and both function and pain scales improved after 9 mo of follow-up. CONCLUSION The FMTP joint injection of mesenchymal stem cells improved symptoms and function in our patient with FMTPA at 9 mo of follow-up.

Report this publication

Statistics

Seen <100 times